PanOxyl Clarifying Exfoliant: the liquid, bottle record and unrelated photos

The manufacturer calls Clarifying Exfoliant a leave-on acne-treatment liquid and names salicylic acid 2%. The US labeling table identifies PanOxyl Clarifying Exfoliant as a salicylic-acid liquid. These records establish the item being discussed without turning it into a cream or a benzoyl-peroxide cleanser. Manufacturer identity and label entry.

That precision prevents PanOxyl’s wider brand identity from replacing the product record. The version guide explains why neighboring items should retain their own names. The format is useful information, but it does not establish a personal application plan, equal exposure to another preparation or a clinical benefit that this publication has measured.

The page publishes salicylic acid as the active and a separate inactive list. Examples include betaine, butylene glycol, glycerin, chamomile extract and Spirulina Platensis extract, which the manufacturer calls blue algae. The posted label supplies the corresponding inactive record. These literal entries improve product identification without demonstrating the quantities or clinical contribution of each component. Manufacturer panel and label ingredients.

FDA explains why inactive ingredients occupy a different field from purpose, uses and warnings. Reading all of those fields is more informative than focusing only on the active percentage. It is not a recipe or a way to predict comfort from an ingredient count. Drug Facts fields.

The label identifies acne medication as the purpose. Its bottle wording also describes pore appearance and a gentle leave-on formula, while the manufacturer page offers a broader pore and complexion story. These statements can be recorded accurately without treating the label as a full clinical study of every advertised appearance benefit. Purpose and bottle wording and manufacturer claims.

The matching-percentage guide considers why a shared active number leaves outcomes unresolved. Here, a purpose field and a pore-appearance statement answer different questions. No complete controlled pore-appearance report was acquired, and the page’s benefit language does not establish how another person will respond to the exact liquid.

The manufacturer page’s before-and-after area includes captions identifying Acne Foaming Wash and Overnight Spot Patches. Those captions are a direct reason not to present the pictures as results from Clarifying Exfoliant. A gallery can appear on an exfoliant page while still showing material attributed to other items in the brand’s range. Gallery captions.

This distinction is more useful than accepting or rejecting every photograph as one group. The relevant question is which exact product each image identifies and what supporting information accompanies it. A neighboring photograph cannot fill the absence of a complete outcome report for this liquid, and the reviewed material does not establish a head-to-head comparison or a universal treatment result.

The label includes a 4 fluid ounce, 118 mL bottle record. The fresh manufacturer page presents a coupon prompt but does not establish a clear exfoliant purchase price in the returned material. Those documents therefore support a package-quantity observation without a verified current price or delivered charge. Package table and current page.

FDA distinguishes quantity from product identity and active strength. The supply-term discussion similarly warns against turning a sales unit into an assumed duration. This review does not infer a monthly cost, redeem the promotion or decide how long the container should last. Retailer price, shipping and actual fulfillment would require their own transaction record. Package-field context.

PanOxyl’s FAQ separately discusses its body spray and identifies Clarifying Exfoliant as the facial preparation. That source distinction helps identify the product, rather than instructing a reader to transfer a spray, wash or other item to a different use. The exfoliant’s own label also contains dryness and irritation cautions alongside its acne-purpose statement. Product-specific FAQ distinction and label warning.

AAD supplies broader context for irritation with salicylic-acid acne care. It does not assess the exfoliant for an individual or cancel the label’s warning because blue algae appears in the formula. The care question remains separate from the brand’s facial-versus-body product description. AAD context.

The posted record names Crown Laboratories, identifies an NDC and an OTC monograph category, and shows a January 2026 revision. These details locate the label version. FDA explains that an NDC is not approval or verification of submitted information, while monograph marketing depends on meeting applicable conditions. Neither field establishes an independently proven clinical advantage. PanOxyl version, NDC limits and monograph framework.

The remaining question concerns the actual bottle and the outcome evidence for this exfoliant alone. The BYOMA review and Naturium review provide further individual records. They are reading links, without transferring another product’s result, assigning a winner or claiming that the posted label settles personal suitability.